01.08.20

Aura Biosciences Appoints George Golumbeski, PhD, as Chairman of the Board of Directors

Source: Aura Biosciences

Aura Biosciences announced the appointment of George Golumbeski, PhD, as Chairman of its Board of Directors. Dr. Golumbeski is a biopharmaceutical business leader with over 25 years of experience in the biotechnology industry.

“George’s extensive experience will be invaluable to Aura as we prepare for upcoming corporate milestones,” Elisabet de los Pinos, PhD, Chief Executive Officer of Aura Biosciences, said in a company news release. “In his prior global leadership roles at Celgene and Novartis, George has overseen successful development, growth and collaboration initiatives that have created significant value and have made a profound impact in many patients’ lives. We welcome George to our team and look forward to working together to bring this new class of innovative therapies to patients with cancer.”

“As an emerging leader in ocular oncology, in late stage development with a new class of targeted therapies, Aura is an exciting growth story, focused on meeting unmet medical needs in oncology,” Dr. Golumbeski said. “Therefore, I am delighted to be joining the team. I look forward to working with the Aura Board and management team to use our collective experience to build the company and to further accelerate the company’s growth.”

In addition to Aura’s Board, Dr. Golumbeski serves on the Board of Directors of several biotechnology companies including: Carrick Therapeutics, Enanta Pharmaceuticals, MorphoSys AG, Verseau Therapeutics, and Sage Therapeutics. Dr. Golumbeski was most recently Executive Vice President of Business Development for Celgene, where he was responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medications to people suffering from cancer and chronic inflammation. Before Celgene, Dr. Golumbeski served as Vice President of Business Development, Licensing and Strategy for Novartis and also held similar senior level business development roles at Elan Pharmaceuticals and at Schwarz Pharma. He holds a bachelor’s degree in biology from the University of Virginia, and a PhD in genetics from the University of Wisconsin-Madison. He conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder.

Related Content